Trial Profile
A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Belzutifan (Primary) ; Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms LITESPARK-003
- Sponsors Peloton Therapeutics
- 24 Oct 2023 Updated results from cohorts 1 (n=50) and 2 (n=52) assessing the efficacy and safety of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma, presented at the 48th European Society for Medical Oncology Congress.
- 21 Oct 2023 According to a Merck & Co Media Release, data from this study are being presented at the ESMO Congress 2023.
- 21 Oct 2023 According to Dana-Farber Cancer Institute Media Release, data from the study were presented at the annual European Society for Medical Oncology (ESMO) Congress.